PPT-Bimekizumab efficacy and safety versus secukinumab in patients with moderate-to-severe
Author : edolie | Published Date : 2023-07-27
Reich K et al Methods Patients with moderatetosevere plaque psoriasis were randomized 11 to Bimekizumab 320 mg every 4 weeks S ecukinumab 300 mg every 4 weeks after
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Bimekizumab efficacy and safety versus s..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Bimekizumab efficacy and safety versus secukinumab in patients with moderate-to-severe: Transcript
Download Document
Here is the link to download the presentation.
"Bimekizumab efficacy and safety versus secukinumab in patients with moderate-to-severe"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents
